Amriti R Lulla

发表

P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9

W. El-Deiry, D. Dicker, X. Tian, 2021, Neoplasia.

P53-independent restoration of p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9

W. El-Deiry, D. Dicker, X. Tian, 2020, bioRxiv.

CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA

W. El-Deiry, D. Dicker, Amriti R Lulla, 2018, Cell cycle.

Bcl-2 Protein Targeting by the p53/p21 Complex-Letter.

W. El-Deiry, X. Tian, Amriti R Lulla, 2018, Cancer research.

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy

H. Lee, Amriti R Lulla, P. Gokare, 2014, F1000Research.

From TRAIL to ONC201: Case Study on the Safety Benefit of Developing Targeted Agents Against Cancer-selective Pathways

W. El-Deiry, Amriti R Lulla, Avital Lev, 2018, Early Drug Development.

Discovery and clinical introduction of first-in-class imipridone ONC201

Neel S. Madhukar, Michael L. Wang, O. Elemento, 2016, Oncotarget.

ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer

W. El-Deiry, D. Dicker, Amriti R Lulla, 2018, Molecular Cancer Research.

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

U. McDermott, M. Garnett, C. Benes, 2018, Cell cycle.

miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells.

Yan Zhou, M. Einarson, W. El-Deiry, 2017, Cancer research.

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

Yan Zhou, C. Benes, W. El-Deiry, 2017, Oncotarget.

Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer

W. El-Deiry, D. Dicker, Amriti R Lulla, 2017, Cancer biology & therapy.

Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation.

W. El-Deiry, D. Dicker, Amriti R Lulla, 2016, Cancer research.

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors

Neel S. Madhukar, O. Elemento, U. McDermott, 2017, PloS one.

Role of Dopamine Receptors in the Anticancer Activity of ONC201

W. El-Deiry, D. Dicker, Amriti R Lulla, 2017, Neoplasia.

ONC201: a new treatment option being tested clinically for recurrent glioblastoma.

W. El-Deiry, Amriti R Lulla, Jessica Wagner, 2017, Translational cancer research.

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212

C. Benes, W. El-Deiry, Amriti R Lulla, 2017, Cell cycle.

Abstract 2942: TRAIL pathway inducer ONC201/TIC10 primes multiple myeloma cells (MM) for apoptosis by downregulating X-linked inhibitor of apoptosis

W. El-Deiry, D. Dicker, Amriti R Lulla, 2015 .

Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins

W. El-Deiry, D. Dicker, Amriti R Lulla, 2014 .

LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers

L. Meijer, Jing Wang, K. Hunt, 2021, Oncogenesis.

miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells.

Yan Zhou, W. El-Deiry, D. Dicker, 2022, American journal of cancer research.